1. Home
  2. EPR vs EWTX Comparison

EPR vs EWTX Comparison

Compare EPR & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EPR Properties

EPR

EPR Properties

N/A

Current Price

$59.92

Market Cap

4.4B

Sector

Real Estate

ML Signal

N/A

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

N/A

Current Price

$46.47

Market Cap

4.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EPR
EWTX
Founded
1997
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
4.3B
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
EPR
EWTX
Price
$59.92
$46.47
Analyst Decision
Hold
Strong Buy
Analyst Count
12
13
Target Price
★ $64.14
$55.42
AVG Volume (30 Days)
879.5K
★ 1.6M
Earning Date
10-28-2026
11-04-2026
Dividend Yield
★ 6.32%
N/A
EPS Growth
★ 105.00
N/A
EPS
2.75
★ 8.86
Revenue
★ $718,357,000.00
N/A
Revenue This Year
$9.61
N/A
Revenue Next Year
$6.54
N/A
P/E Ratio
$21.53
★ $5.19
Revenue Growth
★ 2.91
N/A
52 Week Low
$48.36
$19.76
52 Week High
$64.97
$48.78

Technical Indicators

Market Signals
Indicator
EPR
EWTX
Relative Strength Index (RSI) 57.86 62.79
Support Level $59.63 $37.22
Resistance Level $60.21 $47.36
Average True Range (ATR) 1.38 3.14
MACD 0.19 0.94
Stochastic Oscillator 75.00 80.22

Price Performance

Historical Comparison
EPR
EWTX

About EPR EPR Properties

EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Share on Social Networks: